Phase I Open-Label Dose-Escalating Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs SC-43 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors SupremeCure Pharma
- 03 Apr 2019 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
- 03 Apr 2019 Planned primary completion date changed from 1 May 2020 to 1 May 2021.
- 03 Apr 2019 Planned initiation date changed from 1 Nov 2018 to 1 Nov 2019.